Büşra Fırlatan

GLOBAL-PAN is a worldwide global collaboration of EUVAS, VCRC and many national cohorts as TRVaS Turkish Vasculitis Study Group. linkedin.com/posts/omer-kar…

Our new meta-analysis has just been published! 🎉 PARP inhibitors may be linked to increased VTE risk overall ↗️ (2.4% vs 1.6%; OR 1.37; 95% CI 1.00–1.88). Signals vary by cancer type 🧬 Highlights: • Prostate cancer: higher VTE risk (OR 1.98; P=0.03) 📌 • Pancreatic cancer: notably higher (OR 7.22; P=0.02) ⚠️ • Risk appears context-dependent (tumor type, combinations) 🔄 • Personalized risk assessment is crucial for patients on PARPi ✅ Cohort: 38 RCTs, 15,008 patients across ovarian, prostate, breast, NSCLC/SCLC, pancreatic, glioblastoma, and gastric. Read the paper 🔗 authors.elsevier.com/sd/article/S20… @yekeduz_emre @Erman_Akkus @maxinesun @Silke_Gillessen @fizazi_karim @DrRanaMcKay @Cihan_Ay_MD @Ecastromarcos @NeerajKA @DrChoueiri @DrYukselUrun @ESMO_Open @AUTF_DEKANLIK #Oncology #VTE #Thrombosis #PARPi #CancerResearch #ProstateCancer

Enhancing Outcomes in mCRPC: The Impact of Androgen Receptor Inhibitor Sequencing Before 177Lu-PSMA-617 Therapy academic.oup.com/oncolo/advance… In this retrospective analysis of 214 patients with metastatic castration-resistant #ProstateCancer (mCRPC) treated with ¹⁷⁷Lu-PSMA-617, prior use of enzalutamide—compared to abiraterone acetate (AA)—was associated with significantly improved overall survival (12.8 vs. 6.9 months) and higher PSMA expression. While the difference in progression-free survival between the groups did not reach statistical significance, multivariate analysis confirmed ARPI type and ECOG performance status as independent predictors of survival. These findings suggest that enzalutamide may enhance the efficacy of PSMA-targeted radioligand therapy and underscore the importance of treatment sequencing in mCRPC. @coskunyazgann @hatice_bolek @nahit_sendur @drdeniztural @yekeduz_emre @OncoAlert @silkegillessen @AOmlin @nataliagandur @bavilima @yekeduz_emre

🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior enzalutamide ⬇️ 6.9 months with prior abiraterone acetate 🧠 This difference may be related to enzalutamide’s potential effect on PSMA expression, though the mechanism remains to be clarified. 🔄 These findings highlight the potential importance of treatment sequencing in advanced prostate cancer. 🙏 Thanks to everyone who contributed! 🔗 [Full study here] academic.oup.com/oncolo/advance… #Oncology #NuclearMedicine #ProstateCancer @DrYukselUrun @yekeduz_emre @hatice_bolek @nahit_sendur @drdeniztural

🥁🥁🥁 Thrilled to share that our latest paper is now OUT 📢🥳 🎉It is a distinct honor to share an article with esteemed scholars whose work has profoundly shaped the #ProstateCancer from the past to the future🔝🔝🔝 🎯Key findings from meta-analysis of 3 pioneer trials (HORRAD, STAMPEDE, and PEACE-1): ❌Addition of RT to SOC did not improve rPFS or OS in the overall mCSPC population. ✅In low-volume disease, RT with SOC and abiraterone acetate improved rPFS significantly (HR = 0.65, 95% CI: 0.45–0.93; p = 0.02) without an OS benefit. ➡️➡️➡️ Although no OS improvement was observed, the synergy between AA and RT underscores the value of RT for carefully selected patients. @yekeduz_emre @DrYukselUrun @MutlaySayan @PrafulRavi1 @DrRanaMcKay @hatice_bolek @AlbertoBossial @Prof_Nick_James @Silke_Gillessen @DrChoueiri @AnkaraUni @DanaFarber_GU @OncoAlert @APCCC_Lugano 🖱️doi.org/10.1016/j.euo.…

Shaping the future of survivorship in CSI Testicular GCT! 🌟 Congrats to rising stars @hatice_bolek & @coskunyazgann and @yekeduz_emre for their impactful work. Grateful to @ASCO for this platform! #Oncology #Cancer #GCT @OncoAlert @neerajaiims @AnkaraUni @DanaFarber dailynews.ascopubs.org/do/survivorshi…

Proud and more than happy to be a part of such hardworking @TRVaS Turkish Vasculitis Study Group. Our supplement including invited reviews of @HUVasculitis Workshop 2023 on air! All pdf’s are free access. @EUVAS19 @EgpaGroup @Hacettepe1967 #vasculitis #steroid #glucocorticoid

I am delighted to share the news that our study has been published!🥳 I sincerely thank my esteemed mentors, @DrYukselUrun and @yekeduz_emre, for their unwavering support and invaluable contributions throughout this journey 🙏 @hatice_bolek @AUTF_DEKANLIK #ProstateCancer#Oncology

Excited to share our latest publication! Grateful to be part of such an outstanding team and deeply thankful to my exceptional mentees for their invaulable contributions. @hatice_bolek @yekeduz_emre @DrYukselUrun

🎉Congratulations to Our Honorable Mention Authors! 🏅 We are excited to recognize the following authors whose abstracts received honorable mentions at the GRAPPA Annual Meeting and Trainee Symposium 2024 #GRAPPA2024 #PsoriasisResearch #PsAResearch #HonorableMentions #GRAPPAMeeting #TraineeSymposium

Exciting leadership changes at the Young-GRAPPA Annual Meeting! @ProftDr transitions to Past Chair, @Dr_AndreRibeiro takes over as Chair, and @drgizemayan steps up as Chair-Elect. Ensuring continuity and growth for our young investigators! #Rheumatology #YoungGRAPPA